이상반응 보고
| VAERS ID | 2166889 |
|---|---|
| 성별 | 남성 |
| 나이 | |
| 주 코드 | FR |
| 제약회사 | PFIZER\BIONTECH |
| 로트 번호 | FG7387 |
| 예방접종 횟수 | 3 |
| 접종일 | 2021-09-17 |
| 발병일 | 2022-02-15 |
| 상태 | 사망 |
증상
- SARS-CoV-2 테스트(SARS-CoV-2 test)
- 소변 분석(Urine analysis)
- 코로나 바이러스 감염증 -19 : 코로나 19(COVID-19)
- 초음파 스캔(Ultrasound scan)
- 사구체 여과율(Glomerular filtration rate)
- 혈액 크레아티닌(Blood creatinine)
- 체온(Body temperature)
- 예방접종 실패(Vaccination failure)
- 혈액 나트륨(Blood sodium)
이환 중 질병
지병
Medical History/Concurrent Conditions: Cognitive function abnormal; Hyperplasia of prostate; Splenectomy
기타 의료
Flector [Diclofenac Epolamine]; Mirtazapine; Lamaline [Caffeine; Papaver Somniferum Latex; Paracetamol]; Uvedose; Risperdal; Alprazolam; Movicol [Macrogol 4000;Potassium Chloride; Sodium Bicarbonate; Sodium Chloride]
이전 예방접종
알레르기
임상 검사
Test Date: 20220215; Test Name: creatinine; Result Unstructured Data: Test Result:239 umol/l; Test Date: 20220215; Test Name: Natremia; Result Unstructured Data: Test Result:167 mmol/L; Test Date: 20220214; Test Name: body temperature; Result Unstructured Data: Test Result:38 Centigrade; Comments: fever; Test Date: 20220215; Test Name: CKD-EPI; Result Unstructured Data: Test Result:20; Comments: units: ml/min/1.
7; Test Date: 20220215; Test Name: Test SARS-CoV-2; Test Result: Positive ; Comments: omicron variant; Test Date: 20220215; Test Name: renal ultrasound; Result Unstructured Data: Test Result: Absence of argument for acute obstructive renal fa; Comments: Absence of argument for acute obstructive renal failure; Test Date: 20220202; Test Name: cytobacteriological examination of urine; Result Unstructured Data: Test Result: positive and initiation of levofloxacin until 12Fe; Comments: positive and initiation of levofloxacin until 12Feb2022 (but taken randomly by the patient).
증상 상세
This is a spontaneous report received from a contactable reporter(s) (Physician) from the Regulatory Authority-WEB.
Regulatory number: FR-AFSSAPS-RE20220409 (RA).
A 92 year-old male patient received bnt162b2 (COMIRNATY), intramuscular, administration date 17Sep2021 (Lot number: FG7387) as dose 3 (booster), single, intramuscular, administration date 02Feb2021 (Lot number: EJ6788) as dose 2, single and intramuscular, administration date 12Jan2021 (Lot number: EJ6795) as dose 1, single for covid-19 immunisation.
Relevant medical history included: "Hyperplasia of prostate" (unspecified if ongoing); "Cognitive function abnormal" (unspecified if ongoing); "Splenectomy" (unspecified if ongoing).
Concomitant medication(s) included: Flector [Diclofenac Epolamine]; Mirtazapine; Lamaline [Caffeine; Papaver Somniferum Latex; Paracetamol]; Uvedose; Risperdal; Alprazolam; Movicol [Macrogol 4000;Potassium Chloride; Sodium Bicarbonate; Sodium Chloride].
The following information was reported: VACCINATION FAILURE (death) with onset 15Feb2022, outcome "fatal", described as "Vaccination failure"; COVID-19 (death) with onset 15Feb2022, outcome "fatal", described as "Covid-19".
The patient underwent the following laboratory tests and procedures: blood creatinine (59-104): (15Feb2022) 239 umol/l; blood sodium (136-145): (15Feb2022) 167 mmol/L; body temperature: (14Feb2022) 38 Centigrade, notes: fever; glomerular filtration rate (normal low range 90): (15Feb2022) 20, notes: units: ml/min/1.
7; sars-cov-2 test: (15Feb2022) positive, notes: omicron variant; ultrasound scan: (15Feb2022) absence of argument for acute obstructive renal failure, notes: Absence of argument for acute obstructive renal failure; urine analysis: (02Feb2022) positive and initiation of levofloxacin until 12fe, notes: positive and initiation of levofloxacin until 12Feb2022 (but taken randomly by the patient).
Therapeutic measures were taken as a result of vaccination failure, Covid-19.
The patient date of death was 17Feb2022.
The reported cause of death was Covid-19.
It was not reported if an autopsy was performed.
Additional information: USUAL TREATMENTS: - Alprazolam 0.
25 mg: 1-0-1 (unknown laboratory).
- Mirtazapine 15 mg: 0-0-1 (unknown laboratory).
- UVEDOSE 100,000 IU/2ml: once a week.
HISTORY OF THE DISEASE: Patient at risk of developing a severe form of COVID-19.
On 02Feb2022: ECBU (cytobacteriological examination of urine) positive and initiation of levofloxacin until 12Feb2022 (but taken randomly by the patient).
On 09Feb2022: The patient presents with diarrhea and anorexia.
On 13Feb2022: Alteration in the general condition of the patient.
On 14Feb2022: The patient presents with a fever of 38 centigrade and tachycardia.
On 15Feb2022: Failed vaccination with COVID-19 infection.
Hospitalization of the patient.
The patient presents with acute functional renal failure on dehydration with hypernatremia.
Implementation of rehydration.
Also initiation of CALCIPARINE 5000 IU x2 per day and CEFOTAXIME MYLAN.
On 16Feb2022: The patient deteriorates respiratory requiring oxygen therapy.
Discontinuation of Cefotaxime Mylan and initiation of Piperacillin/Tazobactam Mylan and a bolus of Amikacin Mylan.
Due to the general condition of the patient, decision not to resuscitate the patient if clinical deterioration.
17Feb2022: Introduction of comfort treatment with MIDAZOLAM MYLAN and MORPHINE AGUETTANT.
Death of the patient.
No follow-up attempts are possible.
No further information is expected.
Reported Cause(s) of Death: COVID-19.